US · Healthcare · Medical Care Facilities
EPS came in at -0.08 against a street estimate of -0.07 — a miss of 14.3%.
Analysts rate Starling Oncology, Inc. a strong buy (5 buy, 0 hold, 0 sell out of 5) with an average price target of $9.40.
| Fund | Stake |
|---|---|
| BlackRock Inc | 4.66% |
| Deerfield Management Co | 3.30% |
| Vanguard Capital Management, LLC | 3.20% |
| JOSH ARNOLD INVESTMENT CONSULTANT, LLC | 2.42% |
| Geode Capital Management, LLC | 1.86% |
| The Goldman Sachs Group Inc | 1.70% |
| Wexford Capital LP | 1.68% |
| State Street Corp | 1.52% |
| Document | Date |
|---|---|
| Board / officer change · Q3 2026 STARLING ONCOLOGY, INC. - FORM 8-K SUMMARY HEADLINE NUMBERS • No financial data provided in this filing • Company: Starling Oncology, Inc. (ticker: S | 2026-09-02 |
| Material agreement · Q3 2026 STARLING ONCOLOGY, INC. - FORM 8-K SUMMARY HEADLINE NUMBERS • New revolving credit facility: $25 million aggregate principal amount • Amount drawn a | 2026-08-21 |
| Quarterly report · Q2 2026 STARLING ONCOLOGY, INC. – FORM 10-Q SUMMARY Quarter Ended June 30, 2026 --- HEADLINE NUMBERS • Total Revenue (Q2 2026): $161.3 million, up 34.6% vs | 2026-08-06 |
| Results announced · Q3 2026 STARLING ONCOLOGY Q2 2026 EARNINGS SUMMARY HEADLINE NUMBERS • Q2 2026 consolidated revenue: $161.3 million, up 34.6% from $119.8 million in Q2 2025 | 2026-08-06 |
| Charter / bylaws change · Q3 2026 SUMMARY: THE ONCOLOGY INSTITUTE, INC. (NOW STARLING ONCOLOGY, INC.) HEADLINE NUMBERS • Company name changed from "The Oncology Institute, Inc." to "S | 2026-08-03 |
| Quarterly report · Q1 2026 THE ONCOLOGY INSTITUTE, INC. – Q1 2026 10-Q SUMMARY HEADLINE NUMBERS • Total Revenue (Q1 2026): $147.4 million, up 41% from $104.4 million in Q1 202 | 2026-05-07 |
| Proxy statement · Q2 2026 THE ONCOLOGY INSTITUTE, INC. — PROXY STATEMENT SUMMARY CEO COMPENSATION & CHANGE • Daniel Virnich (CEO) Total 2025 Compensation: Document does not p | 2026-04-30 |
| Annual report FY2025 THE ONCOLOGY INSTITUTE, INC. – FORM 10-K SUMMARY HEADLINE NUMBERS • Company: The Oncology Institute, Inc. (TOI), traded on Nasdaq under ticker TOI • | 2026-03-12 |
Readable in the app.
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Starling Oncology, Inc. — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-11-07.